X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3191) 3191
Book Chapter (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Magazine Article (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2978) 2978
female (2693) 2693
breast cancer (2021) 2021
oncology (1656) 1656
triple negative breast neoplasms - drug therapy (1559) 1559
triple negative breast neoplasms - pathology (1515) 1515
cell line, tumor (1301) 1301
animals (992) 992
cancer (983) 983
triple negative breast neoplasms - metabolism (967) 967
triple negative breast neoplasms - genetics (952) 952
middle aged (865) 865
chemotherapy (860) 860
triple-negative breast cancer (813) 813
mice (723) 723
adult (717) 717
metastasis (694) 694
expression (684) 684
tumors (665) 665
prognosis (640) 640
aged (618) 618
apoptosis (555) 555
gene expression (509) 509
breast neoplasms - pathology (491) 491
breast neoplasms - drug therapy (489) 489
cell proliferation - drug effects (484) 484
survival (459) 459
antineoplastic agents - pharmacology (457) 457
cancer therapies (442) 442
analysis (431) 431
xenograft model antitumor assays (424) 424
antineoplastic combined chemotherapy protocols - therapeutic use (417) 417
treatment outcome (403) 403
care and treatment (399) 399
breast neoplasms - metabolism (396) 396
research (394) 394
apoptosis - drug effects (390) 390
antineoplastic agents - therapeutic use (384) 384
gene expression regulation, neoplastic (379) 379
triple negative breast cancer (379) 379
cell biology (373) 373
therapy (361) 361
medical prognosis (345) 345
health aspects (335) 335
proteins (332) 332
cells (312) 312
medicine & public health (308) 308
mice, nude (304) 304
receptor, erbb-2 - metabolism (299) 299
disease-free survival (293) 293
research article (290) 290
immunohistochemistry (286) 286
growth (275) 275
signal transduction (273) 273
genetic aspects (271) 271
metastases (266) 266
triple negative breast neoplasms - mortality (264) 264
breast neoplasms - genetics (261) 261
receptors, estrogen - metabolism (259) 259
kinases (258) 258
signal transduction - drug effects (256) 256
neoplasm staging (250) 250
neoadjuvant chemotherapy (246) 246
epidermal growth factor (243) 243
gene expression regulation, neoplastic - drug effects (241) 241
neoadjuvant therapy (235) 235
inhibition (233) 233
mutation (233) 233
medicine (232) 232
biochemistry & molecular biology (229) 229
cell survival - drug effects (229) 229
cell proliferation (226) 226
subtypes (226) 226
carcinoma (221) 221
multidisciplinary sciences (221) 221
aged, 80 and over (220) 220
activation (218) 218
patients (218) 218
development and progression (216) 216
neoplasm metastasis (216) 216
receptors, progesterone - metabolism (213) 213
pharmacology & pharmacy (210) 210
identification (203) 203
paclitaxel (203) 203
triple negative breast neoplasms - therapy (201) 201
cell cycle (196) 196
mcf-7 cells (196) 196
stem cells (196) 196
biomarkers (195) 195
kaplan-meier estimate (195) 195
biomarkers, tumor - metabolism (192) 192
neoplasms. tumors. oncology. including cancer and carcinogens (189) 189
resistance (187) 187
mice, inbred balb c (186) 186
retrospective studies (185) 185
cancer research (182) 182
estrogen (182) 182
phosphorylation (180) 180
phenotype (177) 177
triple negative (177) 177
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3170) 3170
Japanese (20) 20
Chinese (14) 14
French (7) 7
German (2) 2
Polish (2) 2
Russian (2) 2
Czech (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of clinical investigation, ISSN 0021-9738, 05/2015, Volume 125, Issue 5, pp. 1801 - 1814
.... In multiple breast cancer cohorts, MEL-18 was markedly downregulated in triple-negative breast cancer (TNBC... 
MEDICINE, RESEARCH & EXPERIMENTAL | BREAST-CANCER CELLS | RESISTANCE | TUMOR-SUPPRESSOR | EXPRESSION | SUMOYLATION | CHEMOTHERAPY | PROGRESSION | E3 UBIQUITIN LIGASE | P53 | Neoplasms, Hormone-Dependent - metabolism | Neoplasms, Hormone-Dependent - mortality | Estrogens | Humans | Drug Resistance, Neoplasm | Sp1 Transcription Factor - metabolism | Receptors, Progesterone - genetics | Polycomb Repressive Complex 1 - genetics | RNA, Messenger - biosynthesis | Receptors, Progesterone - analysis | Carcinoma, Ductal, Breast - drug therapy | Estrogen Receptor alpha - analysis | Carcinoma, Ductal, Breast - pathology | Neoplasm Proteins - genetics | Carcinoma, Ductal, Breast - metabolism | Cysteine Endopeptidases | Endopeptidases - metabolism | Triple Negative Breast Neoplasms - mortality | Breast Neoplasms - drug therapy | Estrogen Receptor alpha - genetics | Polycomb Repressive Complex 1 - physiology | RNA, Neoplasm - biosynthesis | RNA, Neoplasm - genetics | Biomarkers, Tumor - genetics | Estrogen Receptor alpha - biosynthesis | Mice | Neoplasm Proteins - deficiency | Proteasome Endopeptidase Complex - metabolism | Receptor, ErbB-2 - analysis | Neoplasm Transplantation | Neoplasm Proteins - physiology | Triple Negative Breast Neoplasms - drug therapy | Carcinoma, Ductal, Breast - mortality | Tamoxifen - administration & dosage | Breast Neoplasms - metabolism | Polycomb Repressive Complex 1 - deficiency | Sumoylation - drug effects | Protein Processing, Post-Translational - drug effects | Antineoplastic Agents, Hormonal - therapeutic use | Triple Negative Breast Neoplasms - pathology | Female | Aminopyridines - administration & dosage | Antineoplastic Agents, Hormonal - pharmacology | Morpholines - administration & dosage | RNA, Messenger - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Tumor Suppressor Protein p53 - metabolism | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoplasms, Hormone-Dependent - pathology | Triple Negative Breast Neoplasms - metabolism | Tamoxifen - therapeutic use | Tamoxifen - pharmacology | Breast Neoplasms - mortality | Neoplasms, Hormone-Dependent - drug therapy | Progesterone | Biomarkers, Tumor - biosynthesis | Receptors, Progesterone - biosynthesis | Oncology | Endocrinology
Journal Article
PloS one, ISSN 1932-6203, 2016, Volume 11, Issue 6, p. e0157368
Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling... 
TUMOR-INFILTRATING LYMPHOCYTES | SURVIVAL | WOMEN | RATES | IXABEPILONE | MULTIDISCIPLINARY SCIENCES | IDENTIFICATION | PROGNOSTIC VALUE | EXPRESSION | PATHOLOGICAL COMPLETE RESPONSE | PACLITAXEL | Immunohistochemistry | Stromal Cells - pathology | Humans | Laser Capture Microdissection | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Neoplasm Proteins - metabolism | Triple Negative Breast Neoplasms - drug therapy | Triple Negative Breast Neoplasms - classification | Neoplasm Grading | Microarray Analysis | Stromal Cells - drug effects | Female | Retrospective Studies | Neoplasm Proteins - genetics | Gene Expression | Datasets as Topic | Computational Biology | Antineoplastic Combined Chemotherapy Protocols | Triple Negative Breast Neoplasms - mortality | Lymphocytes, Tumor-Infiltrating - drug effects | Disease Progression | Triple Negative Breast Neoplasms - genetics | Lymphocytes, Tumor-Infiltrating - pathology | Neoadjuvant Therapy - methods | Survival Analysis | Mesenchyme | Clinical trials | Oncology | Biochemistry | Metastasis | Datasets | Confidence intervals | Signal transduction | Histopathology | Epidermal growth factor | Lymphocytes | Cell cycle | Bone marrow | Pretreatment | Medical research | BRCA1 protein | Immunomodulation | Breast cancer | Gene expression | Patients | Androgens | Chemotherapy | Biopsy | Stromal cells | Biomarkers | Mutation | Cancer | Tumors
Journal Article
Annals of surgical oncology, ISSN 1534-4681, 2015, Volume 23, Issue 5, pp. 1515 - 1521
No studies have examined the impact of the interval from conclusion of neoadjuvant chemotherapy to surgery in breast cancer patients... 
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | SURGERY | SURGICAL ADJUVANT BREAST | REMOVAL | TRASTUZUMAB | ONCOLOGY | CYCLOPHOSPHAMIDE | INITIATION | TUMOR RESPONSE | POSTOPERATIVE MORBIDITY | RANDOMIZED-TRIAL | PREOPERATIVE DOXORUBICIN | DOCETAXEL | Breast Neoplasms - surgery | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Neoplasm Recurrence, Local - mortality | Triple Negative Breast Neoplasms - drug therapy | Carcinoma, Ductal, Breast - mortality | Mastectomy - mortality | Neoplasm Recurrence, Local - surgery | Neoplasm Recurrence, Local - pathology | Carcinoma, Ductal, Breast - drug therapy | Neoadjuvant Therapy - mortality | Triple Negative Breast Neoplasms - surgery | Triple Negative Breast Neoplasms - pathology | Carcinoma, Ductal, Breast - pathology | Female | Retrospective Studies | Chemotherapy, Adjuvant | Carcinoma, Ductal, Breast - surgery | Time-to-Treatment | Neoplasm Invasiveness | Proportional Hazards Models | Survival Rate | Combined Modality Therapy | Triple Negative Breast Neoplasms - mortality | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Neoplasm Staging | Care and treatment | Cancer patients | Patient outcomes | Analysis | Adjuvant treatment | Breast cancer | Cancer
Journal Article
Anti-cancer agents in medicinal chemistry, ISSN 1871-5206, 02/2017, Volume 17, Issue 2, pp. 152 - 163
Journal Article
Journal Article
International journal of cancer, ISSN 0020-7136, 05/2014, Volume 134, Issue 10, pp. 2424 - 2436
MET, a cell surface receptor for hepatocyte growth factor, is involved in the development of triple‐negative/basal‐like breast cancer (TNBC/BLBC... 
breast cancer | MET | epidermal growth factor receptor | basal‐like | triple‐negative | basal-like | triple-negative | CELLS | HEPATOCYTE GROWTH-FACTOR | ACQUIRED-RESISTANCE | SOMATIC MUTATIONS | KINASE DOMAIN | LUNG-CANCER | ONCOLOGY | C-MET | RECEPTOR MET | CARCINOMA | EXPRESSION | Erlotinib Hydrochloride | Immunohistochemistry | Proto-Oncogene Proteins c-met - metabolism | Humans | Middle Aged | Cell Survival - genetics | Immunoblotting | Sulfones - pharmacology | Triple Negative Breast Neoplasms - drug therapy | Cell Movement - genetics | Breast Neoplasms - metabolism | Neoplasms, Basal Cell - genetics | Receptor, Epidermal Growth Factor - metabolism | RNA Interference | Female | Indoles - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Neoplasms, Basal Cell - drug therapy | Molecular Targeted Therapy - methods | Neoplasms, Basal Cell - metabolism | Cell Survival - drug effects | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Kaplan-Meier Estimate | Reverse Transcriptase Polymerase Chain Reaction | Breast Neoplasms - drug therapy | Proto-Oncogene Proteins c-met - genetics | Cell Movement - drug effects | Breast Neoplasms - genetics | Triple Negative Breast Neoplasms - genetics | Triple Negative Breast Neoplasms - metabolism | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Quinazolines - pharmacology | Breast cancer | Epidermal growth factor | RNA | Drug resistance | Analysis | Cell growth | Chemotherapy | Rodents
Journal Article
Breast cancer research : BCR, ISSN 1465-542X, 2015, Volume 17, Issue 1, p. 25
Introduction: Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer with no effective targeted therapy... 
EPITHELIAL-MESENCHYMAL TRANSITION | CELLS | ACTIVATION | METASTASIS | GENE | ANGIOGENESIS | ONCOLOGY | NITRIC-OXIDE SYNTHASE | ENDOPLASMIC-RETICULUM STRESS | TUMOR-GROWTH | EXPRESSION | Prognosis | Humans | Epithelial-Mesenchymal Transition - genetics | Molecular Targeted Therapy | Triple Negative Breast Neoplasms - drug therapy | Cell Movement - genetics | Lung Neoplasms - secondary | Cell Transformation, Neoplastic - genetics | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Nitric Oxide Synthase Type II - antagonists & inhibitors | Triple Negative Breast Neoplasms - pathology | Female | Antineoplastic Agents - pharmacology | Disease Models, Animal | Gene Expression | Neoplasm Invasiveness | Enzyme Inhibitors - pharmacology | Triple Negative Breast Neoplasms - mortality | Activating Transcription Factor 3 - metabolism | Xenograft Model Antitumor Assays | Cell Movement - drug effects | Animals | Triple Negative Breast Neoplasms - genetics | Nitric Oxide Synthase Type II - genetics | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Triple Negative Breast Neoplasms - metabolism | Endoplasmic Reticulum Stress | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Cell Transformation, Neoplastic - drug effects | Transforming Growth Factor beta - metabolism | Nitric Oxide Synthase Type II - metabolism | Breast cancer | DNA binding proteins | Metastasis | Gene expression | Nitric oxide | Stem cells
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 10, pp. 1360 - 1372
Journal Article
Breast cancer research and treatment, ISSN 1573-7217, 2017, Volume 167, Issue 3, pp. 671 - 686
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 22, pp. 2147 - 2159
Journal Article
Journal Article